0.96
+0.06030002(+6.70%)
Currency In USD
| Previous Close | 0.9 |
| Open | 0.88 |
| Day High | 0.98 |
| Day Low | 0.88 |
| 52-Week High | 9.6 |
| 52-Week Low | 0.61 |
| Volume | 278,563 |
| Average Volume | 487,991 |
| Market Cap | 4M |
| PE | 0.02 |
| EPS | 48.21 |
| Moving Average 50 Days | 0.81 |
| Moving Average 200 Days | 1.54 |
| Change | 0.06 |
If you invested $1000 in Oragenics, Inc. (OGEN) 10 years ago, it would be worth $1.63 as of March 10, 2026 at a share price of $0.96. Whereas If you bought $1000 worth of Oragenics, Inc. (OGEN) shares 5 years ago, it would be worth $15.1 as of March 10, 2026 at a share price of $0.96.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
GlobeNewswire Inc.
Feb 09, 2026 1:30 PM GMT
Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI) Fully prepared to initiate near-term clinical site onboarding and first patient dosing in Australia Sarasota, Fla., Feb. 09, 2026 (GLOBE NEWSWI
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
GlobeNewswire Inc.
Feb 03, 2026 1:30 PM GMT
Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapy Traumatic brain injuries affect more Americans each year than stroke, Alzheimer’s disease, Parkinson’s disease, m
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care
GlobeNewswire Inc.
Feb 02, 2026 1:30 PM GMT
Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”), a clinical-stage biotechnology comp